

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	
)	
Goodchild et al)	Examiner: John Kight III
)	
Serial No. 08/346,270)	Group Art Unit: 1211
)	
Filed November 23, 1994)	
)	
For: Inhibition of HTLV-III by)	
Exogenous Oligonucleotides)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents and Trademarks
Washington, D.C. 20231

Sir:

Pursuant to the duty of disclosure set forth in 37 C.F.R. § 1.56 and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby submit the following documents for the Examiner's consideration:

(1) Renewal Proposal Department of Energy, Contract No. EY-76-S-2404 A001, entitled, "Regulation of Nucleic Acid and Protein Synthesis: A Background Study Related to the Biological Effects of Radiation," for the term October 1, 1979 to September 30, 1980.

(2) Contract between Worchester Foundation for Experimental Biology and The U.S. Department of Energy, Contract No. DE-ACO2-80EV10326, effective October 1, 1979.

(3) Contract Pricing Proposal Cover Sheet for new contract entitled, "Inhibition of Replication and Expression of the HTLVII/LAV Virus by Oligonucleotide Hybridization Competition," date of submission November 15, 1985.

(4) Award/Contract for contract term April 1, 1986 to March 31, 1988, entitled, "Development of ANTI-HTLVIII Specific Agents and Treatment Approaches (Task III).

RECEIVED

2003 APR 14 PM 2:35

BOARD OF PATENT APPEALS
AND INTERFERENCE

(5) Cover Letter from National Cancer Institute, dated April 18, 1986.

(6) Department of Health and Human Services Grant Application entitled, "Oligonucleotide Inhibition of HTLV-III Virus in Culture," dated March 10, 1986.

(7) Notice of Grant Award for "Oligonucleotide Inhibition of HTLV-III Virus in Culture," issued September 30, 1986.

(8) Department of Health and Human Services letter dated October 17, 1995.

A copy of the above noted documents is enclosed, as is a completed copy of the PTO-1449 Form listing the documents. Accordingly, the Examiner is respectfully requested to consider the documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next Official communication.

The present application is involved in an interference and prosecution on the merits thereof has been suspended. For that reason, Applicants do not believe that a fee is due for consideration of the aforesaid documents. However, if a fee is due, this should be considered to be an express authorization for the Commissioner to charge any necessary fee to Deposit Account No. 50-2478.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,



Michael Sofocleous
Reg. No. 45,305
Attorney for the Applicants
703-584-3274

April 9, 2003

Michael Sofocleous
Roberts, Mlotkowski & Hobbes, PC
8270 Greensboro Drive, Suite 850
McLean, VA 22102

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	08/346,270
		Filing Date	11/23/1994
		First Named Inventor	Goodchild et al
		Group Art Unit	1211
		Examiner Name	John Kight III
Sheet 1	of 1	Attorney Docket Number	10767

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Renewal Proposal Department of Energy, Contract No. EY-76-S-02-2404 A001, entitled, "Regulation of Nucleic Acid and Protein Synthesis: A Background Study Related to the Biological Effects of Radiation" for the term October 1, 1979 to September 30, 1980	
	2	Contract between Worchester Foundation for Experimental Biology and The U.S. Department of Energy, Contract No. DE-ACO2-80EV10326, effective October 1, 1979.	
	3	Contract Pricing Proposal Cover Sheet for new contract entitled, "Inhibition of Replication and Expression of the HTLVII/LAV Virus by Oligonucleotide Hybridization Competition," date of submission November 15, 1985	
	4	Award/Contract for contract term April 1, 1986 to March 31, 1988, entitled, "Development of ANTI-HTLVIII Specific Agents and Treatment Approaches (Task III).	
	5	Cover Letter from National Cancer Institute, dated April 18, 1986.	
	6	Department of Health and Human Services Grant Application entitled, "Oligonucleotide Inhibition of HTLV-III Virus in Culture," dated March 10, 1986.	
	7	Notice of Grant Award for "Oligonucleotide Inhibition of HTLV-III Virus in Culture," issued September 30, 1986.	
	8	Department of Health and Human Services letter dated October 17, 1995.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.